Combination strategies to promote sensitivity to cytarabine-induced replication stress in acute myeloid leukemia with and without DNMT3A mutations - Experimental Hematology
Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML | Leukemia
Cancers | Free Full-Text | Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo | HTML
The effects of cytarabine combined with ginsenoside compound K synergistically induce DNA damage in acute myeloid leukemia cells - ScienceDirect
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text
Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis
Patient-Derived Acute Myeloid Leukemia Models | The Jackson Laboratory
Cytarabine Cytosine Arabinoside, Ara-C Chemotherapy Drug Molecule. Used in Treatment of Acute Myeloid Leukemia AML, Acute. Stock Vector - Illustration of arabinofuranosyl, cancer: 187174096
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text
Sequential Treatment with Cytarabine and Decitabine Has an Increased Anti-Leukemia Effect Compared to Cytarabine Alone in Xenograft Models of Childhood Acute Myeloid Leukemia | PLOS ONE
Cytarabine Dose for Acute Myeloid Leukemia | NEJM
SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival | Leukemia
Mitochondrial determinants of response and resistance to venetoclax plus cytarabine duplet therapy in acute myeloid leukemia | bioRxiv
Acute myeloid leukaemia (AML) and cytarabine pharmacogenomics
Enhanced cytarabine-induced killing in OGG1-deficient acute myeloid leukemia cells | PNAS
The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia | Nature Communications
Cytarabine (cytosine Arabinoside, Ara-C) Chemotherapy Drug Molecule. Used in Treatment of Acute Myeloid Leukemia (AML), Acute Stock Illustration - Illustration of lymphocytic, lymphoma: 188460947
Ribonucleotide reductase inhibitors suppress SAMHD1 ara‐CTPase activity enhancing cytarabine efficacy | EMBO Molecular Medicine
Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML—long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance
RO-BIR2 and Ara-C is synergistic in AML cell lines and primary AML... | Download Scientific Diagram
DDA potentiates Ara-C cytotoxicity in AML cell lines and AML from... | Download Scientific Diagram
Cytarabine (cytosine arabinoside, Ara-C) chemotherapy drug molecule. Used in treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and lymphoma. Skeletal formula. Stock Illustration | Adobe Stock
Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota | SpringerLink
Sequential Treatment with Cytarabine and Decitabine Has an Increased Anti-Leukemia Effect Compared to Cytarabine Alone in Xenograft Models of Childhood Acute Myeloid Leukemia | PLOS ONE
Cytarabine (cytosine arabinoside, Ara-C) chemotherapy drug molecule. Used in treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (AL Stock Vector Image & Art - Alamy
